series-a
Stage
1
Investors
About
Arvinas is a biotechnology company that develops therapies using targeted protein degradation (PROTAC) technology to create small-molecule drugs primarily for oncology and neurological diseases.
Explore Arvinas's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.